Gillian Ellsbury

Gillian Ellsbury

Auto-generated profile, based on publicly available information

Gillian Ellsbury

Pfizer Ltd, Tadworth, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2022 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Open access
DMDiana Mendes
Diana Mendes
AAAhuva Averin
Ahuva Averin
MAMark Atwood
Mark Atwood
RSReiko Sato
Reiko Sato
AVAndrew Vyse
Andrew Vyse
TMTendai Mugwagwa
Tendai Mugwagwa
Despite the current pneumococcal vaccination program in England for older adults and adults with underlying conditions, disease burden remains high. We evaluated cost-effectiveness of 20-valent pne...

10 July 2022 in Journal of Medical Economics
Verified
Journal Article
Open access
JCJames Campling
James Campling
HWHannah F. Wright
Hannah F. Wright
GHGillian Hall
Gillian Hall
TMTendai Mugwagwa
Tendai Mugwagwa
AVAndrew Vyse
Andrew Vyse
GEGillian F. Ellsbury
Gillian F. Ellsbury
Accurate and up-to-date figures of the cost of community-acquired pneumonia (CAP) hospitalization are needed to understand the associated economic burden for public health decision makers. Recent e...

8 August 2022 in Expert Review of Vaccines
Verified
Journal Article
Open access
TMTendai Mugwagwa
Tendai Mugwagwa
AAAhuva Averin
Ahuva Averin
MAMark Atwood
Mark Atwood
RSReiko Sato
Reiko Sato
AVAndrew Vyse
Andrew Vyse
DMDiana Mendes
Diana Mendes
Despite use of 23-valent pneumococcal polysaccharide vaccine (PPV23) in England, disease burden among at-risk adults remains high. We evaluated the public health and budgetary impact of 20-valent p...

11 July 2022 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
JCJames Campling
James Campling
EBElizabeth Begier
Elizabeth Begier
AVAndrew Vyse
Andrew Vyse
CHCatherine Hyams
Catherine Hyams
DHDave Heaton
Dave Heaton
GEGillian Ellsbury
Gillian Ellsbury
While incidence studies based on hospitalisation counts are commonly used for public health decision-making, no standard methodology to define hospitals' catchment population exists. We conducted a review of all published community-acquired pneumonia studies in England indexed in PubMed and assessed methods for determining denominators when calculating incidence in hospital-based surveillance studies. Denominators primarily were derived from census-based population estimates of local geographic boundaries and none attempted to determine denominators based on actual hospital access patterns in the community. We describe a new approach to accurately define population denominators based on historical patient healthcare utilisation data. This offers benefits over the more established methodologies which are dependent on assumptions regarding healthcare-seeking behaviour. Our new approach may be applicable to a wide range of health conditions and provides a framework to more accurately determine hospital catchment. This should increase the accuracy of disease incidence estimates based on hospitalised events, improving information available for public health decision making and service delivery planning.

8 March 2022 in Expert Review of Vaccines
Verified
Journal Article
Open access
AVAndrew Vyse
Andrew Vyse
JCJames Campling
James Campling
CCCarole Czudek
Carole Czudek
GEGillian Ellsbury
Gillian Ellsbury
DMDiana Mendes
Diana Mendes
MSMary Paulina Elizabeth Slack
Mary Paulina Elizabeth Slack
Dear EditorWe thank Dr Dawson et al. for their comments [1]. The objective of our review was to focus particularly on the substantial published adult pneumococcal data that have been generated with...